Avicanna $AVCN Cap Table: What the Dilution Bears Get Wrong

So we pulled every financing release & filing on Avicanna $AVCN, counted the paper line by line, & walked into the dark room expecting Jaws. We found a goldfish.

How we got here

Our first piece told you who Avicanna is: a Toronto medical cannabis & biopharma company doing about C$25 million a year of sales, with gross margin at 57% last quarter, up from 51% a year ago, per the Q2 release. This is the balance-sheet chapter, & yes, it opens on a staircase going down.

The company raises money in small bites, each cheaper than the last. A $0.35 unit round whose $0.41 warrants expire December 4. Units with $0.40 warrants in August 2024. Then this year the bites got smaller: four million units at 15 cents in June, 3.3 million more at 15 cents in August, each with half a warrant at $0.20. And on October 29, the one that spooked people, C$2 million of non-convertible debentures at 13% paid monthly, one-year term, 2,000 warrants at $0.20 bolted onto every $1,000 unit. Four million new warrants. The stock closed the next day at $0.105, a hair off its 52-week low.

Now look at who wrote those checks, the part the bears skip. Splash Beverage Group $SBEV, an NYSE American-listed company, put C$300,000 in back in June. Pharma executive & life-sciences investor Michael Porter came in on the August round. The lenders who just handed over C$2 million took their upside in $0.20 warrants, a bet that the stock doubles. Three kinds of money looked at this cap table in 2026, & all three bought.

And look at the sizes. $888K. $600K. $500K. $2 million. This isn’t a company torching $20 million a year & selling stock to cover it. It ran a C$0.28 million working-capital deficit at June 30 & lost C$0.36 million of adjusted EBITDA for the whole quarter. They’ve been topping up the tank, not refinancing the house, & the share count shows it: 125.7 million shares in mid-May, 137.7 million today. Under 10% dilution across three financings & a product launch. In this sector the share count tells the whole story, a point our cannabis sector primer makes too.

What the paper actually says

Here’s the count. Roughly 137.7 million shares. At $0.105 that’s a C$14.5 million market cap, about 0.57 times trailing sales for a 57% gross-margin business. Sit with that for a second. Add about 10 million options, under a million RSUs & roughly 22.5 million warrants, & fully diluted lands near 171 million, a 24% overhang on paper. Management & the board own about 15% of the company between them, & there are no other insiders on the register.

Now the part the ten-cent reflex misses. Every single warrant is underwater. The cheapest strike in the book is $0.20, nearly double the stock price, & the options average $0.34, more than triple it. The dilution that actually hits your per-share math at a dime is basically the RSUs. Everything else is a lottery ticket that only pays the holder after you, the common shareholder, already doubled your money. The stock has to double before the first 7.7 million warrants are even worth exercising, & if it does, the company collects about C$1.5 million in cash for them. Those are the problems you want.

Then there’s the roll-off, & this is the part we like best. About 9 million warrants carry strikes between $0.40 & $0.55, & the bulk of that paper expires over the next year, starting with the $0.41s on December 4. At this price they die worthless, & the warrant book shrinks by close to 40% without the company lifting a finger. The overhang is eating itself. Dilution with a shelf life.

The read on the debentures

You can likely guess where we’re going with this. Management had a choice at a 52-week low: sell stock at a dime, or borrow at 13% with a lien attached & warrants struck at nearly double the price. They borrowed. You don’t do that if you think your stock is headed to a nickel. The cheapest capital on earth is your own equity when you believe it’s overpriced, & they passed on it. A one-year note is a bridge, not a mortgage. Management said in August the back half goes adjusted-EBITDA positive, & they borrowed just enough runway to prove it.

Is 13% expensive? Sure. C$260K a year of interest, due next October, with a security agreement behind it. But a company that won’t sell stock at a dime is telling you where it thinks the stock belongs, & the lenders who priced their warrants at $0.20 agreed.

Why we are optimistic into the print

The business under the paper is turning. Proprietary product units grew 33% year over year & 48% quarter over quarter in Q2. Gross margin went from 51% to 57%. The working-capital hole shrank by a million dollars. QUIX, the rapid-onset line, hit shelves in Q3 with more than 35 listings secured before launch. And there’s a US door we haven’t pulled on yet: the DEA registering hundreds of medical dispensaries last week is the kind of federal move management flagged in August as an opening for its pharma IP. That’s a later chapter.

Retail is pricing $AVCN like the last reel of a horror movie. The paper reads like the first reel of a comeback.

What we’re watching on November 12

Avicanna reports Q3 before the open on Thursday, November 12, with the webcast at 8:30 a.m. ET. Four things, each with a number attached.

Revenue needs to climb back toward the Q1 record of C$6.68 million. Q2 printed C$5.64 million after Veterans Affairs cut its reimbursement rate on April 1, & Q3 is the first quarter with QUIX on shelves. Anything above C$6 million says the VAC hole is being filled with the company’s own higher-margin product.

Adjusted EBITDA needs to turn positive. Management called for it in the second half, & Q3 is half of the second half. Even a small positive number flips the financing story from need to option, & that’s the whole ballgame for a stock at a dime.

Working capital at September 30 needs to show the June deficit didn’t widen while they waited on the debt. The C$2 million landed after quarter-end, so it lives in the subsequent-events note, & we want that note to carry the debentures & nothing else. No new equity. Outcome we’re rooting for: the share count holds at 137.7 million through the December 4 warrant expiry.

And we want QUIX numbers on the call, even early ones. A line that launched with 35 listings should have a first-quarter story to tell.

Bottom line

The villain is in the room. We counted him. He’s a goldfish in a Jaws costume, & a good chunk of the costume expires over the next twelve months. The stock has to double before any of the paper matters, & the business is moving in the direction that gets it there.

Subscribe free at StockAlpha.ai to get the rest of this series & our Q3 reaction the morning it prints.